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ABSTRACT
Objective: To estimate the incidence and analyze any cancer-associated factors in patients with 
Systemic Lupus Erythematosus (SLE) differentiating between hormone-sensitive (HS) and non-HS 
cancers. 
Methods: Retrospective multicentric study of a patient cohort from the SLE Registry of the 
Spanish Society of Rheumatology (RELESSER – Spanish acronym). Included are the following: the 
first cancer post-SLE diagnosis, clinical and sociodemographic information, cumulative damage, 
severity, comorbidities, treatments and refractoriness. Cancers were classified as HS (prostate, 
breast, endometrium and ovarian) and non-HS (the rest). Standardized Incidence Ratio (SIR) was 
calculated and logistic regression models were built. 
Results: 3,539 patients (90.4% women) were included, 154 of whom presented cancer (91% 
women), 44 HS (100% women). Cancer SIR was 1.37 (CI 95%: 1.15-1.59), with higher values in 
women under 65s [2.38 (CI 95%: 1.84-2.91)].  SIR in women with HS vs. non-HS cancer was 1.02 
(CI 95%: 0.13-1.91) and 1.93 (CI 95%: 0.98-2.89)], respectively. In HS vs. non-HS cancers, SLE 
diagnostic age [odds ratio (OR) 1.04 (p= 0.002) vs. 1.04 (p= 0.019), respectively] and period of 
disease evolution [OR 1.01 (p< 0.001) vs. 1.00 (p= 0.029), respectively] were associated with 
cancer. SLICC/ACR damage index [OR 1.27 (p= 0.022)] and ACE inhibitor prescriptions [OR 2.87 
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Conclusion: Cancer incidence in SLE patients is higher than in the Spanish population, particularly 
among young women.  This increase might be due to non-HS cancers, which would be associated 
with an SLE involving greater cumulative damage where more ACE inhibitors are prescribed. 
Keywords: systemic lupus erythematosus, cancer, incidence, hormone-sensitive
SIGNIFICANCE AND INNOVATIONS
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 Cancer risk was higher in women under 65 and those with non-HS cancers.
 SLE diagnostic age and period of disease evolution were common factors associated with 
both HS and non-HS cancers.  
 ACE inhibitor prescriptions and the greater cumulative damage were also associated with 
non-HS cancers.
Cancer is one of the most serious illnesses a person can have, as it affects both the physical and 
emotional state and can sometimes lead to death. Furthermore, when cancer is diagnosed in a 
patient with a chronic autoimmune disease such as systemic lupus erythematosus (SLE), with its 
associated cumulative damage and comorbidities, it presents challenges not only for that patient, 
but also for the doctors assessing and treating both illnesses. At present, there is insufficient 
knowledge regarding the immune system alterations that occur in SLE, changes which may 
influence cancer onset and/or development (1). Several studies carried out in different countries, 
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the general population (2-7). In particular, the cancer standardized incidence ratio (SIR) is higher 
across virtually all anatomic locations (hematological, lung, thyroid, hepatobiliary, vulva-vagina, 
cervix, and pancreas) (2, 3, 5, 6, 8, 9). However, different studies have also highlighted a risk 
reduction in hormone-sensitive (HS) cancers such as breast, endometrial and ovarian (2-4, 10, 
11). It has been suggested that if the metabolism of estrogen or other predominantly female 
hormones was altered in SLE, it could slow the progression of hormone-sensitive cancers. On the 
other hand, a nucleolytic lupus autoantibody, anti-5C6, might help prevent DNA repair 
mechanisms in breast, ovarian, and prostate cancers associated with BRCA2 mutations (12). 
Therefore it is possible that SLE autoantibodies may contribute to a decreased risk of certain 
hormone-sensitive cancers. Thus, it appears that in patients with SLE there might exist some 
differences in the cancers vis-à-vis hormonal dependence, although the exact mechanisms linking 
the immune and endocrine systems to cancer risk are unknown. For this reason, it would be 
interesting to determine whether factors associated with HS cancer differ from those with non-
HS. Most studies have focused on searching for factors associated with cancer onset in SLE and 
have grouped all cancer types, whereas others have explored factors related to the onset of 
hematological, lung and breast cancer. Yet to date no study has explored stratified cancers vis-à-
vis hormone-sensitivity. Thus, an analysis comparing HS and non-HS cancers within a multicentric 
cohort with a large number of patients might expand our understanding in this sense.
The purpose of this study was to estimate the cancer incidence in SLE patients and to analyze 
factors associated with its onset, differentiating between HS and non-HS cancers. 
PATIENTS AND METHODS
1. Design, scope and participants    
A retrospective observational longitudinal study of a cohort of RELESSER registry patients. 
Participants.  RELESSER includes patients over 16 years of age with SLE (per the revised American 
College Rheumatology (ACR) criteria of 1997) (13) from 45 hospitals registered with the Spanish 
Society of Rheumatology (SER) hospital database. At least 80% of patients from each centre were 
included, all of whom having had at least one appointment with a rheumatology department at 
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least 50% of the information deemed essential were excluded. The design, variables, and general 
characteristics of the RELESSER registry have been published previously (14). 
2. Data collection
Rheumatologists with experience in diagnosing and treating SLE patients collected the data from 
each centre, and then uploaded it via an online software application designed ad hoc for the 
project. Data quality control was performed via professional online monitoring. 
3. Variables and operational definitions
The main study variable was the first cancer after SLE diagnosis. Endometrial, breast, ovarian and 
prostate cancers were classified HS and the rest non-HS. Patient follow-up was defined as the 
period between the date of SLE diagnosis and the date of the first cancer for those presenting 
the study event, and the RELESSER data collection date (2010-2011) for patients who did not 
develop cancer. Patients for whom information was unavailable until the data collection date 
were censored to the date of their last appointment at the rheumatology surgery. Secondary 
variables included: 1) sociodemographic; 2) general symptoms; 3) cancer location; 4) 
accumulated SLE symptoms, defined per ACR diagnostic criteria (13, 15) and BILAG definitions 
(16); 5) SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) activity (17, 18); 6) 
damage per the SLICC/ACR DI (Systemic Lupus International Collaborative Clinics/American 
College of Rheumatology Damage Index) (19), excluding cancer; 7) degree of severity (Katz index) 
(20); 8) comorbidities, hospitalizations and causes of death; 9) Charlson comorbidity index, Deyo 
modified version (21); 10) treatments for comorbidities and SLE control; and 11) refractoriness, 
as defined for the registry (22). 
4. Statistical analysis
A descriptive analysis was performed using absolute and relative frequencies of qualitative 
variables, mean or median and dispersion measures (SD: standard deviation, IR: interquartile 
range) for quantitative variables. The accumulated incidence (AI) of cancers in patients included 
in RELESSER for 2011 was calculated. To estimate cancer AI in the general population, cancer 
cases in Spain for 2012 were compiled and measured against the overall population per the 2011 
Housing & Population Census (23, 24). Both AI measures were compared by calculating the 
standardized incidence ration (SIR). The latter was determined at the same time, differentiating 
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Spain during 2014 (25). In addition, the prevalence of cancer globally and per anatomic location 
was estimated. The years between the diagnosis of SLE and the development of the first cancer 
were also calculated, as well as the mortality rate for each cancer type according to anatomical 
location. With a view to analyzing the association between cancer onset and the clinical 
characteristics of SLE patients, a logistics regression model was built to analyze female patients, 
differentiating between HS and non-HS cancer. The Odds Ratio (OR) was calculated for all 
independent variables together with their confidence value (CI) at 95%. Inclusion of independent 
variables in a multivariant model was based on clinical judgment and a p-value < 0.25 obtained in 
the bivariant analysis. The absence of multi-co-linearity among independent variables included 
was checked with the Kappa correlation coefficients in the case of qualitative variables, and with 
the Pearson correlation for quantitative variables. In the final logistic regression model, the 
independent variables were adjusted by all the other model variables.
Ethical aspects: This project complied with principles of the Helsinki Declaration (26). The project 
also received the approval of the general Clinical Research Ethics Committee (CREC) (Doctor 




The total number of patients included in the analysis were 3,539, 90.4% of whom were women 
with a mean age at diagnosis of 35 and a mean period of disease evolution of 143 months (Table 
1). The main characteristics of the registry patients have been published previously (14).
2. Patient characteristics according to cancer presence 
The main characteristics of patients with a first cancer onset since SLE diagnosis compared to 
those without are detailed in Table 1. The total number of patients with cancer was 154 (4.35%), 
91% of whom were women, with a mean diagnostic age of 40.37 (SD 15.7) years. Age at 
diagnosis, the period of disease evolution, Sjögren Syndrome (SS) association, KATZ, SLICC/ACR 










This article is protected by copyright. All rights reserved
However, the SLEDAI and number of hospitalizations due to SLE activity were higher in patients 
without cancer.  
3. Patient characteristics per HS and non-HS cancers
Out of the 154 patients with cancer, only 14 presented in men and none were hormone 
dependent. Table 2 shows the HS and non-HS cancer characteristics in women.  Both the 
SLICC/ACR and Charlson indexes had higher values in patients with non-HS cancers.  
4. Cancer incidence 
Cancer AI in SLE patients was 6.31 cases per 1000 patients (CI 95%: 4.00-9.45). After stratifying by 
age and gender, the group with the highest number of first cancers (16 cases per 1000 patients 
(CI 95%: 6.45-32.65)) was that of women over 64 (Table 3).  Cancer SIR was 1.37 (CI 95%: 1.15-
1.59) and the group with the highest values was that of women under 65, with 2.38 (CI 95%: 
1.84-2.91) (Table 4). In women, HS cancer SIR was 1.02 (CI 95%: 0.13-1.91) and for non-HS 
patients it was 1.93 (CI 95%: 0.98-2.89).
5. Cancer prevalence and distribution 
As to the distribution of cancer according to anatomic location, breast and gynecological cancer 
were the most frequently recorded (23.4% and 20.1%, respectively), followed by hematological 
(75% non-Hodgkin lymphoma (NHL) and 25% Hodgkin lymphoma) and skin (non-melanoma), 
both 11.7%. These were followed by colorectal and thyroid cancer (both 5.2%), lung cancer 
(3.25%), and other locations (19.5%). After analyzing the subgroup of SLE patients with 
associated SS, the most frequent location was breast cancer at 29%, followed by gynecological 
and hematological, both at 16.1%. NHL was the most common hematological cancer (60%) in SLE 
patients with associated SS.   
6. Time frame for cancer onset 
The median time frame until the onset of the first cancer was 10 years (IR: 5.75-17.00), which 
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years], and in patients under 45 [8.0 (IR: 5.00-16.00) years] versus over 45 [10.9 (IR: 7.0-18.6 
years)].  
7. Death due to cancer
Global mortality was 5.5% of patients, with cancer being the fourth leading cause of death, after 
SLE itself, cardiovascular disease and infections. Death due to cancer in patients included in the 
study was 10.66%, with the most prevalent being hematological (19%) and breast (19%) cancers, 
followed by lung (14.3%) and colorectal (9.5%). 
8. Factors associated with cancer onset in women
Tables 5 and 6 show the results obtained in the bivariant analysis of HS and non-HS cancers. 
Regarding the multivariant model, the variables presenting significant associations with HS 
cancer onset were SLE diagnostic age (OR 1.4; CI 95%: 1.01-1.07; p= 0.002) and period of disease 
evolution (OR 1.01; CI 95%: 1.00-1.01; p< 0.001). The multivariate model of non-HS cancers 
showed a significant association with SLE diagnostic age (OR 1.04; CI 95%: 1.01-1.07; p= 0.019), 
evolution period (OR 1.00; CI 95%: 1.00-1.01; p= 0.029), SLICC/ACR DI (OR 1.27; CI 95%: 1.04-
1.57; p= 0.022) and prescription of angiotensin-converting enzyme (ACE) inhibitors (OR 2.87; CI 
95%: 1.01-8.14; p= 0.048) (Tables 5 and  6). 
DISCUSSION
The results obtained in this national retrospective multicentric study showed that the cancer 
incidence in SLE patients is higher than in the general population, with said differences being 
more striking in women under 65, and those with non-HS cancers. Furthermore, breast, 
gynecological and hematological cancers were the most frequently recorded in SLE patients and 
those with associated SS. Onset of the first cancer post-SLE diagnosis occurred around 10 years 
later, with breast and hematological cancers causing more deaths. Both SLE diagnostic age and 
the period of disease evolution were factors associated with HS and non-HS cancers. However, 
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The differences found among patients with and without cancer on the Katz and Charlson indexes, 
as well as a statin prescription, suggest that cancer patients have a more serious clinical state and 
greater risk of comorbidities. These variables had not been analyzed in previous studies, although 
the SLICC/ACR DI had, the latter showing higher values in patients with cancer (27), results 
consistent with our own study. As to the number of hospitalizations per SLE activity, we noted a 
paradox; i.e., patients without cancer were hospitalized more frequently. This might be due to 
the effect of oncological drugs on the activity and evolution of SLE.
On analyzing the differences between women with HS or non-HS cancers, our study revealed that 
the damage associated with SLE and comorbidity was higher only in patients with non-HS 
cancers. Notwithstanding such evidence, these results have yet to be replicated by other groups. 
Nonetheless, we consider this a relevant finding since patients with non-HS cancers might 
require a more complex clinical and therapeutic approach. 
Several studies in different countries, races and ethnic groups have noted a global cancer 
increase with an SIR between 1.14 and 3.6 (1). Likewise, those studies that stratified SIR by 
gender and age found this increase particularly prevalent in women between 21 and 64 years of 
age (2, 28). In our Spanish cohort, the results support previously published findings. Regarding HS 
breast, endometrial and ovarian cancers, a very slight and not significant increase has been 
suggested (29, 30); likewise, a significant drop in SIR has been observed (2, 3, 6, 10, 11). This has 
led to the belief that a direct association cannot be established between SLE and the risk of HS 
cancers. Our study detected a very slight, albeit not significant, increase in SIR in women with HS 
cancers. In non-HS cancers, the increase was higher although it remained at the limit of statistical 
significance. 
Regarding distribution by location, breast, gynecological and hematological (especially NHL) 
cancers were the most prevalent. These three cancers were also among the most frequent in 
other cohorts, which was true of studies carried out on different races or ethnic groups (2-4, 28, 
30).  In fact, this distribution was maintained in SLE and SS patients, with the hematological 
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Focusing on the time frame relationship between SLE and cancer, our patients developed cancer 
post-SLE diagnosis within a median of 10 years (9 years in women under 45). Other authors have 
tackled this time frame relationship via cancer risk stratification (SIR) pursuant to follow-up time. 
They found an increased global cancer risk between under one year and over 8 years from the 
time of SLE diagnosis, with a greater risk during the first year of follow-up (2, 4, 28). 
Among the Spanish population, the cancers most frequently causing death in men are lung, 
colorectal and prostate, while in women they are breast, colorectal and lung (24, 25). In our 
essentially female cohort, the same distribution held true, though hematological cancers also 
met first-line inclusion. This is not surprising given that chronic immune deregulation due to SLE 
is associated with greater lymphoid proliferation, thus increasing the risk of hematological 
tumors, specifically NHL(31). 
We are aware that the global standardized mortality rate for cancer in SLE has not increased (32). 
Patients with chronic diseases are subject to greater vigilance, which may favor early cancer 
diagnosis and improved prognosis. It has also been suggested that SLE patients present a 
competitive premature mortality due to other causes like cardiovascular disease, infections, and 
lupus nephritis (32).  Our results support this suggestion, since cancer was the fourth leading 
cause of death after SLE itself, cardiovascular disease and infections. 
SLE diagnostic age and period of disease evolution were associated with both HS and non-HS 
cancers. In other studies, age was associated with cancer in general, in particular breast cancer 
and lymphomas (27, 33, 34). Bernasky et al. have suggested that lupus duration confers a 
protective effect against cancer onset (27). This potentially contradicts our results, although their 
study had a different design and SLE duration was established from the time the patient was 
included in the cohort, as opposed to the time of SLE diagnosis as in our study. Accumulated SLE 
damage and ACE inhibitor prescriptions were solely associated with non-HS cancers. The 
SLICC/ACR DI was found to be a possible factor associated with cancer (27); however, until now it 
was not known that this association is an underlying factor in non-HS cancers. We have no 
information regarding ACE inhibitor prescriptions as a cancer-associated factor in SLE, since it 
had not been included in previous analyses. In our cohort, those patients with cancer who had 
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than those without ACE inhibitors. The role ACE inhibitors might play in cancer risk is highly 
controversial, not only in SLE but in the general population as well. While some studies suggest 
they may increase the risk of certain cancers, such as in the lung (35), others show a reduction or 
absence of such an association (36).                                  
We found no association between HS cancers and oral contraception, the number of pregnancies 
or menopause, nor has this association been previously demonstrated with breast cancer (33). 
Our results provide evidence that there are several factors exclusively associated with non-HS 
cancers. This would support the hypothesis that there are differences in cancer according to 
hormonal dependence. If these differences are confirmed by subsequent studies, the way 
patients are assessed will also likely change. Preventative measures and/or cancer screening in 
patients with SLE based on the risk associated with hormonal dependence may be adopted.
Our study has several limitations. Its retrospective design might render the results somewhat less 
reliable. Nevertheless, it remains an acceptable design for tackling infrequent events like cancer. 
The increased risk of non-HS cancers was on the threshold of significance, for although the total 
number of cancers was not depreciable when the SIRs of HS and non-HS cancers were separated, 
statistical power was nonetheless lost. The variables included in our model better explain the 
non-HS cancers, which leads us to believe that there are still other variables requiring 
identification and which are associated with HS cancers. 
One of the strengths of this study is that it is the largest SLE multicentric cohort published in 
Europe. In addition, we included variables not previously analyzed in other studies. Moreover, as 
the data were drawn from a clinical registry, as opposed to an administrative national health 
insurance database, we had more detailed information on the disease, allowing us to better 
adjust the models. Finally, the comparison between HS and non-HS cancers had not been 
explored before; as such, it has greatly expanded upon information previously only hypothesized 
regarding the differences among these cancer types.
In conclusion, the cancer incidence in SLE patients is higher than in the general Spanish 
population, particularly in young women. Above all, the incidence rate may be dependent on 
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associated with both HS and non-HS cancers. However, non-HS cancers were also associated with 
ACE inhibitor prescriptions and greater accumulated damage. Further studies confirming our 
findings on the differences between HS and non-HS cancer are greatly warranted, as is a 
renewed search for factors that most clearly determine the risk of such cancers.
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value  YES (n=154) NO (n= 3,385) 
Female, n (%) 3,194 (90.4) 140 (90.9) 3,054 (90.4) 0.821 
Age at first SLE criterion (years), mean (SD) 32.84 (14.4) 38.35 (16.0) 32.72 (14.3) < 0.001 
Age at SLE diagnosis (years), mean (SD) 34.85 (14.5) 40.37 (15.7) 34.75 (14.5) < 0.001 
Age at last assessment (years), mean (SD) 46.52 (14.8) 57.74 (14.4) 46.17 (14.6) < 0.001 
Race, n (%)         
Caucasian 3196 (93.0) 145 (96.7) 3051(92.8) 
0.071 
Others 241 (7.0) 5 (2.7) 236 (7.2) 
Period of disease evolution (months), mean (SD) 142.86 (100.6) 208.71 (103.0) 140.1 (99.7) < 0.001 
Follow-up time in rheumatology dept.  (months), mean (SD) 120 (87.6) 170. 1 (90.8) 118.12 (86.9) < 0.001 
Sjögren Syndrome, n (%) 503 (14.4) 31 (20.5) 472 (14.1) 0.029 
SLEDAI, median [p25-p75] 2 [0-4] 1 [0-3] 2 [0-4] 0.026 
KATZ Index, median [p25-p75] 2 [1-3] 3 [2-4] 2 [1-3] 0.001 
Modified SLICC/ACR DI*, median [p25-p75] 1 [0-2] 1 [0-3] 0 [0-1] < 0.001 
Modified Charlson Index*, median [p25-p75] 2 [1-3] 3 [2-4] 1 [1-3] < 0.001 
Anti-malaria treatment time (months), median [p25-p75] 60 [24-120] 78 [27-136] 60 [24-110] 0.099 
Smoking (past and current smokers), n (%) 1656 (46.8) 76 (49.4) 1580 (46.7) 0.515 
Alcohol, n (%) 111 (3.482) 6 (4.4) 105 (3.4) 0.517 
Statins, n (%) 165 (5.1) 15 (10.7) 150 (4.9) 0.002 
ACE Inhibitors, n (%) 313 (9.7) 20 (14.6) 293 (9.5) 0.05 
Acetylsalicylic acid, n (%) 1061 (37.180) 55 (40.4) 1006 (36.9) 0.408 
Immunosuppressants, n (%) 1939 (57.2) 80 (53.3) 1859 (57.4) 0.326 
Immunosuppressants type         
  Non immunosuppressants, n (%) 2133 (60.3) 98 (63.7) 2035 (60.1) 
0.668   Cyclophosphamide/Mycophenolate/Mycophenolic, n (%) 973 (27.59 38 (24.7) 935 (27.6) 
  Methotrexate/Leflunomide, n (%) 433 (12.3) 18 (11.7) 415 (12.3) 










SD: Standard Deviation; SLE: Systemic Lupus Erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease 
Activity Index; SLICC/ACR DI: Systemic Lupus International Collaborative Clinics/American College of 
Rheumatology Damage Index; ACE Inhibitors: angiotensin-converting enzyme inhibitors; *The score 
corresponding to cancer was excluded when calculating the index. 
 
 
Table 2. Characteristics of women with Systemic Lupus Erythematosus and cancer stratified 
per hormone-sensitivity 
Variables Hormone-sensitive Cancer  p-value 
YES (n=44) NO (n=96) 
Age at first SLE criterion (years), mean (SD) 39.1 (15.6) 37.65 (16.18) 0.582 
Age at SLE diagnosis (years), mean (SD) 41.9 (14.4) 39.58 (16.07) 0.497 
Age at last evaluation (years), mean (SD) 57.9 (13.1) 57.31 (15.29) 0.901 
Race, n (%)       
Caucasian 44 (100) 87 (94.57)                   
0.107 Others 0 (0) 5 (5.43) 
Period of disease evolution (months), mean (SD) 198.8 (85.9) 212.76 (112.33) 0.352 
Follow-up time in rheumatology dept.  (months), mean (SD) 175.66 (81.58) 163.80 (94.78) 0.493 
Sjögren Syndrome, n (%) 11 (26.2) 19 (20) 0.294 
SLEDAI, median [p25-p75] 0 [0-2] 2  [0-4] 0.268 
KATZ Index, median [p25-p75] 2 [2-3] 3 [2-4] 0.059 
Modified SLICC/ACR DI*, median [p25-p75] 1 [0-2] 1.5 [1-3.5] 0.011 
Modified Charlson Index*, median [p25-p75] 2 [2-3] 3 [2-4.5] 0.034 
Anti-malaria treatment time (months), median [p25-p75] 84 [19-144] 74.5 [32-133.5] 0.715 
Smoking (past and current smokers), n (%) 22 (60.0) 44 (45.83) 0.78 
Alcohol, n (%) 1 (2.9) 2 (2.27) 0.779 
Statins, n (%) 2 (5.4) 8 (8.89) 0.425 
ACE Inhibitors, n (%) 4 (10.8) 11 (12.64) 0.735 
Corticoids at maximum doses, occasionally, n (%) 776 (27.4) 36 (27.1) 740 (27.4) 0.93 
Hospitalization per activity, n (%) 1902 (54.6) 88 (57.9) 1814 (54.5) 0.41 
Nº  of hospitalizations per activity, median [p25-p75] 2 [1-3] 2 [1-3] 2 [1-4] 0.01 










Acetylsalicylic acid, n (%) 15 (38.5) 33 (39.29) 0.836 
Immunosuppressants, n (%) 19 (46.3) 53 (55.79) 0.188 
Type of Immunosuppressants       
  Non immunosuppressants, n (%) 31 (70.5) 59 (61.46) 
      
0.314 
  Cyclophosphamide/Mycophenolate/Mycophenolic, n (%) 8 (18.2) 25 (26.04) 
  Methotrexate/Leflunomide, n (%) 5 (11.4) 12 (12.5) 
Oral contraceptives, n (%) 9 (32.1) 16 (23.19) 0.307 
Corticoids at maximum doses, occasionally, n (%) 6 (16.7) 24 (28.92) 0.163 
Hospitalization per activity, n (%) 21 (50.0) 57 (59.38) 0.382 
Nº of hospitalizations per activity, median [p25-p75] 2 [1-3] 2 [1-3] 0.257 
Refractoriness, n (%) 8 (18.2) 25 (26.04) 0.194 
SD: Standard Deviation; SLE: Systemic Lupus Erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease 
Activity Index; SLICC/ACR DI: Systemic Lupus International Collaborative Clinics/American College of 
Rheumatology Damage Index; ACE Inhibitors: angiotensin-converting-enzyme inhibitors; *The score 





















Table 3. Accumulated incidence of cancer in RELESSER patients and general population per the 2012 Cancer Registry of the National Institute of Statistics, 
stratified by age and gender 
 
RELESSER* GENERAL POPULATION£ 
Age Men Women Total Men Women Total 
< 65 years, AI (CI 95%) 
≥ 65 years, AI (CI 95%) 


































Table 4. Standardized Incidence Ratio of cancer (nº cancer cases observed /nº of expected 
cancer cases) stratified by age and gender 




Age Men Women Total 
< 65 years, SIR (CI 95%) 1.51 (0.62-2.40) 2.38 (1.84-2.91) 2.16 (1.71-2.61) 
≥ 65 years, SIR (CI 95%) 0.59 (0.0-1.26) 1.55 (1.15-1.95) 0.98 (0.73-1.23) 










Table 5. Factors associated with hormone-sensitive cancers in women with Systemic Lupus Erythematosus 
Variable Bivariant  Multivariant  
 
OR (CI95%) p-value OR (CI95%) p-value 
Age at first SLE criterion (years) 1.03 (1.01-1.05) 0.001   
Age at SLE diagnosis (years) 1.03 (1.01-1.05) 0.001 1.04 (1.01-1.07) 0.002 
Age at last evaluation (years) 1.05 (1.03-1.07) <0.001   
Race     
Caucasian (reference)     
Others     
Period of disease evolution (months) 1.00 (1.00-1.01) 0.001 1.01 (1.00-1.01) <0.001 
Follow-up time in rheumatology dept. (months) 1.01 (1.00-1.01) < 0.001   
Sjögren Syndrome 1.94 (0.98-3.94) 0.057 1.60 (0.72-3.53) 0.246 
SLEDAI  0.89 (0.78-1.01) 0.063 0.94 (0.82-1.08) 0.394 
KATZ Index 0.96 (0.80-1.16) 0.707   
Modified SLICC/ACR DI* 1.11 (0.95-1.29) 0.188   
Modified Charlson Index* 1.27 (1.10-1.46) 0.001   
Anti-malaria treatment time (months)  1.00 (1.00-1.00) 0.818   
Smoking (past and current smokers) 1.25 (0.69-2.26) 0.464   
Alcohol  1.40 (0.19-10.36) 0.745   
Statins 1.07 (0.26-4.50) 0.925   
ACE inhibitors 1.22 (0.43-3.48) 0.706   
Acetylsalicylic acid 1.10 (0.57-2.11) 0.772   
Immunosuppressants 0.66 (0.36-1.23) 0.188   
Type of Immunosuppressants     
  Non immunosuppressants (reference)     
  Cyclophosphamide   
/Mycophenolate/Mycophenolic,  
0.60 (0.27-1.30) 0.194   
   Methotrexate/Leflunomide 0.78 (0.30-2.03) 0.618   










SLE: Systemic Lupus Erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; 
SLICC/ACR DI: Systemic Lupus International Collaborative Clinics/American College of Rheumatology 
Damage Index; ACE Inhibitors: angiotensin converting-enzyme inhibitors; *The score corresponding to 





Corticoids at maximum dose, occasionally 0.55 (0.23-1.33) 0.186 0.74 (0.29-1.85) 0.516 
Hospitalization per activity 0.89 (0.48-1.63) 0.699   
Nº of hospitalizations per activity 1.01 (0.86-1.19) 0.887   
Refractoriness 0.72 (0.33-1.55) 0.394   
Anti-DNA 0.69 (0.37-1.30) 0.249 0.88 (0.40-1.92) 0.75 
Nº of pregnancies 1.19 (1.01-1.39) 0.038 1.00 (0.80-1.25) 0.987 










  Table 6. Factors associated with non-Hormone-sensitive cancer in women with Systemic Lupus Erythematosus.  
Variables Bivariant  Multivariant  
 
OR (IC 95%) p-value OR (IC 95%) p-value 
Age first criterion (years) 1.03 (1.01-1.04) < 0.001   
Age at SLE diagnosis(years) 1.02 (1.01-1.04) < 0.001 1.04 (1.01-1.07) 0.019 
Age at last evaluation (years) 1.05 (1.03-1.07) <0.001   
Race     
Caucasian (reference)  0.478   
Others 0.72 (0.29-1.79)   
Period of disease evolution (months) 1.01 (1.00-1.01) <0.001 1.01 (1.00-1.01) 0.029 
Follow-up time in rheumatology dept. (months) 1.01 (1.00-1.01) < 0.001   
Sjögren Syndrome 1.39 (0.83-2.31) 0.213 0.95 (0.35-2.57) 0.246 
SLEDAI  0.96 (0.90-1.02) 0.209 0.97 (0.86-1.09) 0.394 
KATZ Index 1.16 (1.05-1.29) 0.005   
Modified SLICC/ACR DI * 1.32 (1.21-1.43) < 0.001 1.27 (1.04-1.57) 0.022 
Modified Charlson Index* 1.43 (1.31-1.56) < 0.001   
Anti-malaria treatment time  (months)  1.00 (1.00-1.00) 0.264 1.00 (1.00-1.00) 0.947 
Smoking (past and current smokers) 1.06 (0.70-1.59) 0.791   
Alcohol 1.10 (0.27-4.59) 0.893   
Statins 1.83 (0.87-3.86) 0.112 0.33 (0.04-3.04) 0.329 
ACE inhibitors§ 1.46 (0.77-2.78) 0.25 2.87 (1.01-8.14) 0.048 
Acetylsalicylic acid  1.14 (0.73-1.78) 0.565   
Immunosuppressants 0.96 (0.64-1.46) 0.864   
Type of Immunosuppressants     
  Non immunosuppressants (reference)     
  Cyclophosphamide 
/Mycophenolate/Mycophenolic,  
0.98 (0.61-1.57) 0.929   
   Methotrexate/Leflunomide 0.99 (0.53-1.86) 0.975   











SLE: Systemic Lupus Erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLICC/ACR DI: 
Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index; ACE 
Inhibitors: angiotensin converting-enzyme inhibitors; *The score corresponding to cancer was excluded when 
calculating the index. §Cancer patients prescribed ACE Inhibitors were more commonly hypertensive than those not 
prescribed these (75% vs. 41%, p=0.005); furthermore, they were more frequently diagnosed with lupus nephritis 
(85% vs. 18.8%, p<0.001). 
 
 
Corticoids at maximum dose, occasionally 1.12 (0.69-1.82) 0.638   
Hospitalization per activity 1.30 (0.86-1.96) 0.219 0.52 (0.22-1.26) 0.148 
Nº of hospitalizations per activity 1.10 (1.04-1.17) 0.001   
Refractoriness 1.13 (0.71-1.80) 0.597   
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